Relay Therapeutics Stock Performance
| RLAY Stock | USD 4.75 0.11 2.37% |
The company holds a Beta of 3.98, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Relay Therapeutics will likely underperform. At this point, Relay Therapeutics has a negative expected return of -0.43%. Please make sure to check Relay Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Relay Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Relay Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.94 | Five Day Return (15.99) | Year To Date Return (60.12) | Ten Year Return (86.50) | All Time Return (86.50) |
1 | Relay stock rallies 41 percent on positive data for RLY-2608 | 09/09/2024 |
2 | Strength Seen in Relay Therapeutics Can Its 6.7 percent Jump Turn into More Strength | 09/17/2024 |
3 | Disposition of 1657 shares by Peter Rahmer of Relay Therapeutics at 11.16 subject to Rule 16b-3 | 09/23/2024 |
4 | Disposition of 295 shares by Thomas Catinazzo of Relay Therapeutics at 7.51 subject to Rule 16b-3 | 10/01/2024 |
5 | Biotech layoff tracker 13 biotechs cut over 1,400 jobs | 10/02/2024 |
6 | Short Interest in Relay Therapeutics, Inc. Grows By 24.7 | 10/15/2024 |
7 | Institutional owners may consider drastic measures as Relay Therapeutics, Inc.s recent US67m drop adds to long-term losses | 10/28/2024 |
8 | Disposition of 2300 shares by Thomas Catinazzo of Relay Therapeutics at 5.95 subject to Rule 16b-3 | 10/29/2024 |
9 | Relay Therapeutics, Inc. CFO Thomas Catinazzo Sells 6,802 Shares | 10/31/2024 |
10 | Relay Therapeutics Issues Earnings Results | 11/07/2024 |
11 | Cornercap Investment Counsel Inc. Trims Holdings in Relay Therapeutics, Inc. | 11/19/2024 |
12 | Down -27.93 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround | 11/20/2024 |
| Begin Period Cash Flow | 154.4 M |
Relay |
Relay Therapeutics Relative Risk vs. Return Landscape
If you would invest 726.00 in Relay Therapeutics on August 25, 2024 and sell it today you would lose (251.00) from holding Relay Therapeutics or give up 34.57% of portfolio value over 90 days. Relay Therapeutics is currently does not generate positive expected returns and assumes 7.5454% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Relay, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Relay Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relay Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Relay Therapeutics, and traders can use it to determine the average amount a Relay Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0574
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RLAY |
Estimated Market Risk
| 7.55 actual daily | 67 67% of assets are less volatile |
Expected Return
| -0.43 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Relay Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Relay Therapeutics by adding Relay Therapeutics to a well-diversified portfolio.
Relay Therapeutics Fundamentals Growth
Relay Stock prices reflect investors' perceptions of the future prospects and financial health of Relay Therapeutics, and Relay Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Relay Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (39.47) % | ||||
| Current Valuation | (13.14 M) | ||||
| Shares Outstanding | 167.38 M | ||||
| Price To Book | 0.93 X | ||||
| Price To Sales | 77.62 X | ||||
| Revenue | 25.55 M | ||||
| Gross Profit | 1.38 M | ||||
| EBITDA | (374.15 M) | ||||
| Net Income | (341.97 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 8.72 X | ||||
| Total Debt | 53.47 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.22 X | ||||
| Book Value Per Share | 5.03 X | ||||
| Cash Flow From Operations | (300.32 M) | ||||
| Earnings Per Share | (2.61) X | ||||
| Market Capitalization | 776.66 M | ||||
| Total Asset | 843.98 M | ||||
| Retained Earnings | (1.4 B) | ||||
| Working Capital | 739.83 M | ||||
About Relay Therapeutics Performance
Evaluating Relay Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Relay Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Relay Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 963.23 | 1,011 | |
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.45) | (0.43) |
Things to note about Relay Therapeutics performance evaluation
Checking the ongoing alerts about Relay Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Relay Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Relay Therapeutics generated a negative expected return over the last 90 days | |
| Relay Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (341.97 M) with profit before overhead, payroll, taxes, and interest of 1.38 M. | |
| Relay Therapeutics currently holds about 1.05 B in cash with (300.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Down -27.93 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround |
- Analyzing Relay Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Relay Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Relay Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Relay Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Relay Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Relay Therapeutics' stock. These opinions can provide insight into Relay Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.